The core original members of the IBTN team are drawn from a variety of areas and countries. These international experts have many years of experience in developing and delivering behavioural trials and a number of them have been involved in some of the largest trials in our field. They have pulled together this expertise to create the IBTN and through this work hope to improve the quality and quantity of behavioural interventions and trials.

Interested in joining our group? Contact us

Simon L. Bacon, PhD (co-lead)

Dr. Simon Bacon, co-Director of the Montreal Behavioural Medicine Centre and Director of the Centre de Readaptation Jean-Jacques-Gauthier, has had extensive training in the delivery of behavioural randomised controlled trials and has been a PI and co-I on 12 different studies involving behavioural interventions, including exercise, weight management, stress management, and motivational interviewing. In addition, he has several years in generating national recommendations through his work with the Canadian Hypertension Education Program (CHEP: he has been a member of the last 5 recommendation panels), where he is currently the chair of the lifestyles sub-committee. Finally, Dr. Bacon has organised several knowledge translation events, including Café Scientifiques, where he has brought a number of different stakeholders together to discuss key topics and issues, for example, trying to create a common dialogue between researchers and the media to improve health innovation reporting.


Kim Lavoie, PhD (co-lead)

Dr. Kim Lavoie, co-Director of the MBMC and Director of the Chronic Disease Research Division at Hôpital du Sacré-Coeur de Montréal, is a Full Professor in the Department of Psychology at the University of Quebec at Montreal. She is internationally recognized for her research on the impact of psychological and behavioural factors on the development and progression of cardiovascular and lung diseases, and the impact of behavioral interventions, e.g., motivational communication, exercise, and behavioural weight loss, on key health behaviours and outcomes in chronic lung disease. She is also the Chair of Health Psychology and Behavioural Medicine at the Canadian Psychological Association and an active member of the CHEP recommendation panel (Adherence Subcommittee). She has been involved in numerous meeting planning committees (both nationally and internationally) including the American Psychosomatic Society’s annual meeting and the Canadian Institute of Health Research’s (CIHR) Young Investigator Forum meetings (5 years). Finally, she is an internationally recognized expert in motivational communication; over 8000 health professionals across Canada, the US, Europe (France, Spain, Germany, The Netherlands, Belgium, Switzerland, Portugal, Italy, Estonia, the UK) and Australia/New Zealand have attended her professional training workshops. She currently holds a CIHR Investigator Award and multiple grants in the area of motivational communication training and efficacy for behaviour change in chronic disease.


Gregory Ninot, PhD (co-lead)

Dr. Grégory Ninot is a Professor at the University of Montpellier (France). He leads the CEPS Platform, which is dedicated to improving the methodology of behavioral trials. Dr. Ninot plays a critical coordination role in the development of the quality of these studies in Europe. He is involved in several clinical trials testing the efficacy of exercise programs, e-health solutions, psychotherapy or therapeutic education methods mainly in patients with respiratory disease or cancer. He has published over one hundred articles and more than a dozen books on the subject. He writes a blog to raise public awareness of randomized controlled trials, with the ultimate goal of improving care for chronic disease patients.

Jean Bourbeau, PhD

Dr. Jean Bourbeau, respirologist and Associate Professor in the Department of Medicine and Epidemiology & Biostatistics at McGill University, is the director of the Respiratory Epidemiology and Clinical Research Unit (RECRU) and the Pulmonary Rehabilitation Unit at the Montreal Chest Institute of the McGill University Health Centre (MUHC). His areas of research and expertise are in COPD, Rehabilitation and Disease and Self-management. He has a particular interest in behavioural Randomized Clinical Trials around pulmonary rehabilitation and his work has not only had impact in research but also in clinical practice and the public domain (e.g., Living Well with COPD). In addition, Dr. Bourbeau is the director of the COPD axis of the Respiratory Network of the Fonds de la recherche en santé du Quebec (FRSQ), Quebec, Canada. He is the president-elect of the Canadian Thoracic Society (CTS) and member on the COPD committee. He is also on the executive committee and the chair of the Dissemination & Implementation committee of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Through these networks Dr. Bourbeau will be able provide additional knowledge translation opportunities to advance the work of the network.

Isabelle Boutron, PhD

Dr. Isabelle Boutron, Professor of Clinical Epidemiology at the University Paris Descartes and a researcher at the INSERM U738, is an expert in the methodological characterization and evaluation of non-pharmacological treatments, risk of bias in trials, and the problems of knowledge and transparency of research. She has a strong focus on the internal validity of non-pharmacological trials, especially around blinding, where she has published extensively in most of the high ranking medical journals. Through her work with the Bias Method Group of the Cochrane Collaboration, the French Cochrane Centre, and CONSORT group she has been able to participate in the development of international recommendations to improve the transparency of trials assessing nonpharmacological treatments, including being the lead author on the CONSORT non-pharmacological interventions extension. Along with her colleagues she has also published a highly acclaimed book entitled “Randomized Clinical Trials of Nonpharmacological Treatments.”Finally, she has been currently working on a new concept: the “spin”, i.e., how the presentation, interpretation and / or inappropriate discussion of results may bias the interpretation of readers, which is a critically important aspect of the knowledge translation process.

Tim Caulfield, PhD

Dr. Tim Caulfield, Canada Research Chair in Health Law, Trudeau Fellow and Professor at the Faculty of Law and School of Public Health and Policy, and Research Director of the University of Alberta Faculty of Law’s Health Law Institute, is an internationally recognized scholar for his work in the areas of health law and science policy. Broadly his research explores the ethical, legal and social issues associated with a wide range of topics, including stem cell research, genetics, patient safety, the prevention of chronic disease, obesity policy, the commercialization of research, complementary and alternative medicine and access to health care. His extensive work exploring key research ethics issues (consent, right to withdrawal, incidental findings, duty of care etc.), challenges around health policy implementation, and behavioral change in the context of genetic risk information (i.e. does it’s provision influence the recipients psychological state and/or subsequent behavior) and through the use of incentives (i.e. in the context of obesity policy) is particularly relevant for the proposed initiative. His research investigating the impact/influence of popular media/representations on issues such as policy development and resource allocations is also highly significant. As well, Professor Caulfield has been involved with a number of national and international policy and research ethics committees, including the Canadian Biotechnology Advisory Committee, Genome Canada’s Science Advisory Committee, the Ethics and Public Policy Committee for the International Society for Stem Cell Research and the Federal Panel on Research Ethics (in which he played a key role in the drafting of the 2nd edition of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS)). He has organized and hosted numerous knowledge translation events — including Café Scientifiques, public panels, and consensus workshops –is interviewed and writes frequently for the popular press, and publishes extensively.

Susan Czajkowski, PhD

Dr. Susan Czajkowski, Chief of the Health Behaviors Research Branch (HBRB) of the National Cancer Institute (NCI), is an expert on psychosocial and behavioral risk factors for disease, including the role of social support and depression in disease risk and recovery; the development and testing of interventions for behavioral risk factors such as obesity, physical inactivity, adverse diets, and non-adherence to medical regimens; and the assessment of health-related quality of life and psychosocial functioning in patients with chronic diseases. She has managed several research initiatives involving improvement of adherence to lifestyle and medical therapies in patient populations, including minority patients and the medically underserved and was project officer for the Enhancing Recovery in Coronary Heart Disease (ENRICHD) Patients Study, the largest multicenter clinical trial to evaluate the effects of treating depression and low social support in heart attack patients. As lead project officer for the NIH-funded Obesity-Related Behavioral Intervention Trials (ORBIT) network, Dr. Czajkowski and Dr. Lynda Powell led the development of the ORBIT model for preventing and treating chronic diseases. Dr. Czajkowski is a fellow in the Society of Behavioral Medicine, and recently served as President of the Academy of Behavioral Medicine Research.

Karina Davidson, PhD

Dr. Karina Davidson, Professor of Behavioral Medicine in Medicine and Psychiatry at Columbia College of Physicians and Surgeons and Director of the Center for Behavioral & Cardiovascular Health, is an expert on behavioral and psychosocial interventions for patients with cardiovascular disease and she has conducted randomized controlled trials of anger management and depression treatment for both hypertensive and post-myocardial infarction patients. Her research team recently completed a multi-site, multi-project NIH contract exploring the etiology, course and randomized controlled treatment of depressive symptoms in patients with acute coronary syndromes, and this research continues by examining depression phenotypes and their biobehavioral mechanisms in a NHLBI-funded program project. Most recently they conducted an NHLBI-funded randomized controlled trial to test if enhanced depression treatment vs. current treatment improves survival in acute coronary disease patients at sites across the U.S. Other research activities include being the Convening Chair of the Cochrane Behavioral Medicine Field, an international effort to review and synthesize evidence for behavioral medicine interventions. She also formed and was the Chair of the Evidence-based Behavioral-Medicine committee, a task force charged by 7 national and international societies with improving and implementing evidence-based principles within behavioral medicine. Finally, Dr. Davidson led the NIH-funded Summer Institute on Conducting Randomized Controlled Trials with Behavioral Interventions, a U.S-based effort to improve the expertise of the next generation of leaders in behavioural trials.

Kenneth Freedland, PhD

Dr. Kenneth Freedland, Professor of Psychiatry and Psychology, Washington University School of Medicine, is an expert in the behavioural treatment of depression and related problems in medically ill patients. He has been the principal investigator or a co-investigator on a number of single-site and multicenter trials of treatments for depression in patients with coronary heart disease, heart failure, diabetes, lung disease, or other conditions. For example, Dr. Freedland was a co-investigator and clinical supervisor for the multicenter Enhancing Recovery in Coronary Heart Disease (ENRICHD), a co-investigator and assessment core leader for the multicenter CODIACS Vanguard trial, and a co-investigator and clinical supervisor for the multicenter INSPIRE trial of stress management for lung transplant candidates. He has also been the P.I. on several behavioural intervention trials, including an ongoing RCT of a cognitive-behavioural intervention for depression and self-care in patients with heart failure. In addition, Dr. Freedland is a founding fellow of the Academy of Cognitive Therapy (ACT) and an ACT-certified cognitive therapy trainer, an instructor in clinical trial methodology on the faculty of the National Institutes of Health annual Summer Institute on Randomized Behavioural Clinical Trials, and the author of a number of published articles and book chapters on behavioural trial methodology. He has a particular interest in the selection and design of control groups for behavioural trials.

Gaston Godin, PhD

Dr. Gaston Godin, Professor Emeritus at Laval University (Quebec City, Canada), is an expert in behavioural sciences in the domain of health. He is also responsible of the research group on behaviours in the domain of health. He has conducted several intervention projects, aimed at changing different behaviours such as use of condoms, practicing regular physical activity, eating fruit and vegetables, giving blood, etc… These projects have adopted various methodological approaches including randomized controlled trials. He also participated as an expert in the Behavioural Change Techniques (BCT) taxonomy project funded by the UK Medical Research Council. He also collaborated with the international Workgroup for Intervention Development and Evaluation Research (WIDER) group and colleagues supporting WIDER’s aims. WIDER’s overarching aim is to improve the scientific reporting of behavior change interventions (BCIs) and evaluations of BCIs in accordance with CONSORT statements.

Susan Michie, PhD

Dr. Susan Michie is Professor of Health Psychology at University College London (UCL) and Director of its Centre for Behaviour Change and of the Health Psychology Research Group. She is also Co-Director of the BPS’s Centre for Outcomes Research and Effectiveness and Co-Director of the National Centre for Smoking Cessation and Training. Susan is a chartered clinical and health psychologist, whose research focuses on behaviour change in relation to health: how to understand it theoretically and apply theory to intervention development and evaluation, and to evidence synthesis. This is conducted in the domains of risky and preventive behaviours amongst the general population (e.g. smoking, alcohol use, preparing for pandemic flu), managing illness (e.g. medication adherence), and professional practice and implementation (e.g. hand-hygiene amongst hospital staff). Her work includes developing and evaluating digital interventions and investigating the fidelity of delivery of interventions. Her research develops methods to advance the study of behaviour change, including frameworks such as the Behaviour Change Wheel and the Theoretical Domains Framework, and specifying intervention content using taxonomies of behaviour change techniques (BCT Taxonomy v1). Of note, she has authored two recent books, The Behaviour Change Wheel Guide to Designing Interventions and ABC of Behaviour Change Theories, both published in 2014.

David Moher, PhD

Dr. David Moher is a Senior Scientist at the Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI). Dr. Moher is also an Associate Professor in the School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, where he holds a University Research Chair. Dr. Moher is the principal investigator on several Canadian Institutes of Health Research (CIHR) grants including a network meta-analysis program, several systematic reviews and Cochrane Canada. He is also a co-convenor of the Bias Methods Group of the Cochrane Collaboration. For a decade Dr. Moher was the Director of the University of Ottawa’s Evidence-based Practice Centre, one of 14 such centres in North America, funded by the U.S. Agency for Healthcare Research and Quality. Dr. Moher is also known for is for his leadership in developing guidelines for reporting health research, including the internationally-adopted CONSORT guidance for randomized trials, and the PRISMA statement for reporting systematic reviews. Dr. Moher is associated with many journals; the founding editor-in-chief of Systematic Reviews; a member of the advisory board for the International Congress on Peer Review and Biomedical Publication, and a member of the EQUATOR Network’s steering group. Dr. Moher has a Masters degree in Epidemiology and a PhD in Clinical Epidemiology and Biostatistics.

Paul Montgomery, PhD


Dr. Paul Montgomery is Professor of Psycho-Social Interventions at Oxford University and lead on the development of the CONSORT-SPI, a reporting guideline for randomised trials of complex psychological and social interventions. His research focuses on improving our understanding of what interventions are effective in tackling complex psychological, social, and health problems. His academic work spans a range of issues, from chronic sleep problems to HIV/AIDS, and integrates the use of several high-quality methodological approaches, many of which have not been traditionally applied in the social sciences. This work falls under three broad categories: (1) Methodology of Psycho-Social Intervention, (2) Nutrition, and (3) Behavioural Interventions. This work has been widely published and he has received funding from multiple sources. A social worker by training, Paul maintains a clinical practice on top of his academic work, where he specialises in Brief Intervention and Cognitive Behavioural techniques for depression, anxiety and insomnia, and treats both adults and adolescents.

Lynda Powell, PhD

Dr. Lynda Powell is the Charles J. and Margaret Roberts Professor of Preventive Medicine, Medicine (Cardiology), Behavioral Sciences, and Pharmacology and Chairman, Department of Preventive Medicine and Rush University Medical Center. Her research specializes in the development and delivery of behavioral randomized clinical trials to promote cardiovascular health. Dr. Powell has been the Principal Investigator of 5 major randomized behavioral clinical trials and a founding faculty member and Co-Director of the NIH-OBSSR Summer Institute on Behavioral Clinical trials, now in its twelfth year. Of note in the context of the current application, Dr. Powell is a Principal Investigator of the NIH-funded ORBIT network which includes 7 sites all of whom are in the process of developing behavioral interventions for obesity and she has been intimately involved in the creation of the Intervention Development Model for Behavioral Trials.

Lise Rochaix, PhD

Dr. Lise Rochaix is full time member of the executive board of the French national health authority (HAS – Haute Autorité de Santé) and chairs the economics and public health assessment committee (CEESP – Commission d’Evaluation Economique et de Santé Publique). She is currently in secondment from the University of Aix-Marseille II where she holds a chair in the economics department. Her research interests include regulatory issues in the healthcare sector, in particular, performance payments as well as and equity measurement. She earned her Ph.D from York University, UK.

David Secko, PhD

Dr. David Secko, Associate Professor of Journalism at Concordia University (Montréal), is an expert in public engagement. His research links across journalism, science and ethical issues to clarify and experiment with the roles of the public, experts and journalists in the democratic governance of biotechnology. He has helped develop a structured deliberative engagement methodology (see: Genomics, Society and Policy 6(1): 16-33; Canadian Journal of Communication 35(2): 265-274; Social Science and Medicine 68: 781-789; Personalized Medicine 5(3): 285-296) that has been tested in 15 public engagement events since 2006 on a diverse range of topics, such as biobanking, pharmacogenomics, health journalism, salmon genomics, the bioeconomy and biofuels. Dr. Secko is also a trained facilitator. He won a Concordia University Research Award for his research contributions in 2011, the Dean’s Award for excellence as a new scholar in 2010 and was awarded the Hal Straight Gold Medal in Journalism from UBC’s School of Journalism in 2006. Examples of his other research interests include a recent qualitative metasynthesis of the experiences of a science journalists (Science Communication 34, 2: 241-282) and a narrative analysis of online commentary after science stories (Journalism 12, 7: 814-31).

Stan Shapiro, PhD

Dr. Stanley Shapiro is a Professor in the Department of Epidemiology and Biostatistics, McGill University, and a consultant to the Randomized Clinical Trial Unit at the Jewish General Hospital. He received his PhD (1972) and MSc (1968) in statistics from Stanford University and BSc in mathematics (1967) from Bucknell University. In addition to McGill he has held positions at Acadia University (Asst Prof ’71-’73), Harvard (Visiting Assoc Prof ’80-’81) and Michigan (Visiting Prof ’86-). He is the co-editor of Clinical Trials Issues Approaches. He currently serves on a number of trial Scientific Advisory Committees and Data Safety and Monitoring Boards, and recently completed extended service on the Medical Research Council (Canada) clinical trials grants committee and the data safety and monitoring committee of the Canadian HIV Clinical Trials Network. He is a member of the Biometric Society, the American Statistical Society, the Statistical Society of Canada, and the Society for Clinical Trials among others. His long-standing research interests centre on theoretical and applied aspects of clinical trials, and he publishes in both the statistical and health sciences literature. Current methodologic research interests include non-compliance in clinical trials, dissemination of clinical trial results, and operationalizational aspects of clinical equipoise.

Bonnie Spring, PhD

Dr. Bonnie Spring, Professor of Preventive Medicine, Psychology, and Psychiatry at Northwestern University and Director of the Center for Behavior and Health of its Institute for Public Health and Medicine, is recognized internationally for her research on interventions to improve risk behaviors for chronic disease. Her research on smoking, physical inactivity, and obesity has been funded continuously since 1976 primarily by grants from the NIH (NHLBI, NIDDK, NCI, NIMH), American Heart Association, American Cancer Society, and Department of Veterans Affairs. She has been PI of a number of clinical trials fostering smoking cessation and reduction of weight gain via pharmacological and behavioral treatments. A NIDA-funded effectiveness trial that delivers her intervention using the nationwide tobacco telephone quit lines is currently ongoing. She has also been PI of several trials using technology-supported interventions to foster change in multiple diet and activity behaviors or weight loss. Her current trials implement novel research designs adapted from engineering science to optimize and increase the efficiency of behavioral intervention development. She serves on the American Psychological Association’s Advisory Steering Committee to Develop Clinical Treatment Guidelines, Chairs the American Heart Association’s Health Behavior Change Committee, and her NIH-funded on-line learning modules on evidence-based practice are freely accessible online (   She is also founding editor and editor-in-chief of Translational Behavioral Medicine: Practice, Policy, Research.